Xenon Inhalation for Treatment of Panic Disorder

• Status: Not yet recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a double-blind, randomized, placebo-controlled, clinical trial in parallel groups in patients with panic disorder.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nobilis Therapeutics Inc.
• Treatments: Xenon

Criteria

Inclusion Criteria:

• Primary diagnosis of panic disorder according to DSM-5.

• Male and female patients ≥18 years of age.

Exclusion Criteria:

• History of schizophrenia, bipolar and other psychotic disorders.

• Patients with underlying pulmonary disease, chronic obstructive pulmonary disease (COPD), asthma, severe lung disease and/or baseline oxygen saturations <92% or any other respiratory conditions / diseases that may affect the respiratory function.

• Currently undergoing targeted empirically-driven psychotherapy for panic disorder or panic disorder-related symptoms.

• Currently undergoing exposure-based psychotherapy for any condition.